Events & Training for March 2020

AI in Drug Discovery Conference 2020

16 March 2020 - 17 March 2020

SMi group presents the launch of the inaugural AI in Drug Discovery conference taking place in London on 16th-17th March 2020. AI-empowered machine learning technologies hold the potential of reducing drug discovery associated costs by US$ 70 billion in the upcoming 10 years. With an estimated +39% CAGR, AI in drug discovery is leading the way into a shorter, cheaper and more successful R&D era where compound generation is automated, drug synthesis is predictable and undruggable diseases are finally being targeted. The presence of AI in drug discovery is tangible with the majority of drug discovery scientist already working with AI-enabled platforms using machine learning and deep learning, neural networks and natural language processing. However, there is a long journey ahead of optimizing AI-human connections and understanding the full potential of AI-enabled tools and platforms.

Copthorne Tara Hotel, London, UK

Future Health

17 March 2020 - 18 March 2020

Future Health 2020 organized in association with UKIHMA – a UK government trade promotion organization jointly funded by the Department for International Trade, the Department of Health and NHS England, is the UK’s only exhibition and conference showcasing healthcare products and services to a global audience. Taking place at Olympia London from 17-18 March 2020, Future Health gathers more than 4,000 buyers from 65 countries for two days of education, networking and cross border purchasing.

Kensington Olympia, London, UK

Venture Summit | West

23 March 2020 - 24 March 2020

Drug Discovery Today is pleased to announce its sponsorship and invite you to join us at Venture Summit | West Special offer: Register Now & Save $450 off (Use discount code “DRUGDISCOVERYTODAYVIP") * Call for Top Innovators

Santa Clara Convention Center, Silicon Valley

SMi’s 22nd Annual Superbugs & Superdrugs Conference

30 March 2020 - 31 March 2020

A Focus on Non-traditional Approaches in the Fight against Antimicrobial Resistance As one of the most impactful pharmaceuticals for maintaining public health, antibiotics have been around since early 20th century and have since shown a need for significant progress in recent years. This is mainly due to its broad and indiscriminate use which has slowly given birth to multi- to extensively-drug resistant bacteria rendering our current last-resort antibiotic arsenal, including colistin, carbapenems, 3rd and 4th generation cephalosporins, useless. This year’s event aims to showcase a suite of sessions focused on novel drugs and approaches, particularly highlighting non-traditional and traditional therapies that provide an innovative means to spearhead the issue. The conference will also place significant emphasis on the much-needed support for innovative approaches such as sessions tackling the funding and support and the regulation that provides guidance towards the goal of ameliorating the continued rise of anti-microbial resistance AMR. It is crucial to bring industry leaders together to discuss the strategies in place that reduce AMR, evaluate the role pharmaceutical companies and funding bodies play in reducing AMR, learn about new diagnostics approaches to identify AMR and consider novel candidates and alternatives to anti-microbials. Join us in March 2020, along with leaders from the pharmaceutical industry, academia, regulatory and funding bodies, and public-private partnerships to discuss the way forward. #SMiBugs

Holiday Inn Kensington Forum, London, UK

SMi’s 22nd Annual Superbugs & Superdrugs Conference

30 March 2020 - 31 March 2020

A Focus on Non-traditional Approaches in the Fight against Antimicrobial Resistance As one of the most impactful pharmaceuticals for maintaining public health, antibiotics have been around since early 20th century and have since shown a need for significant progress in recent years. This is mainly due to its broad and indiscriminate use which has slowly given birth to multi- to extensively-drug resistant bacteria rendering our current last-resort antibiotic arsenal, including colistin, carbapenems, 3rd and 4th generation cephalosporins, useless. This year’s event aims to showcase a suite of sessions focused on novel drugs and approaches, particularly highlighting non-traditional and traditional therapies that provide an innovative means to spearhead the issue. The conference will also place significant emphasis on the much-needed support for innovative approaches such as sessions tackling the funding and support and the regulation that provides guidance towards the goal of ameliorating the continued rise of anti-microbial resistance AMR. It is crucial to bring industry leaders together to discuss the strategies in place that reduce AMR, evaluate the role pharmaceutical companies and funding bodies play in reducing AMR, learn about new diagnostics approaches to identify AMR and consider novel candidates and alternatives to anti-microbials. Join us in March 2020, along with leaders from the pharmaceutical industry, academia, regulatory and funding bodies, and public-private partnerships to discuss the way forward. #SMiBugs

Holiday Inn Kensington Forum, London, UK